GlassScriptPhysician profile
Bright Ohene Odei
NPI 1023423308
$957.90
in general payments reported to CMS, 2019-2025
17 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $44.52 · 2023: $369 · 2024: $239 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $757.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $137.02 | 2023-2024 | Repatha |
| Lilly USA, LLC | $123.73 | 2023-2025 | Mounjaro, Zepbound |
| Mauna Kea Technologies, INC. | $118.21 | 2019 | |
| Inspire Medical Systems, INC. | $86.01 | 2023-2025 | Inspire |
| Abbvie INC. | $82.53 | 2019-2020 | |
| Glaxosmithkline, LLC. | $77.95 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Mylan Specialty L.P. | $42.52 | 2023 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $41.55 | 2023 | Farxiga, Breztri |
| Corcept Therapeutics | $39.41 | 2025 | Korlym |
| Exact Sciences Corporation | $38.34 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $31.45 | 2023-2025 | Ozempic, Rybelsus |
| Medtronic, INC. | $29.09 | 2023 | Intellis Adaptivestim |
| Actelion Pharmaceuticals US, INC. | $28.16 | 2023 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $26.56 | 2024 | |
| Pfizer INC. | $20.49 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $17.50 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.38 | 2023 | Tradjenta, Trijardy Xr, Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bright Odei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.